Last updated: February 25, 2026
What is VABOMERE?
VABOMERE (meropenem-vaborbactam) is a combination antibiotic indicated for complicated urinary tract infections (cUTI) and complicated intra-abdominal infections (cIAI). Approved in 2018 by the FDA, it counters multidrug-resistant bacteria, especially carbapenem-resistant Enterobacteriaceae (CRE).
What are the Excipient Components in VABOMERE?
VABOMERE comprises:
- Meropenem: a carbapenem antibiotic
- Vaborbactam: a beta-lactamase inhibitor
The formulation contains excipients designed for stability, solubility, and patient safety. The excipient details are as follows:
| Excipients |
Purpose |
Typical Content |
Regulatory Notes |
| Sodium carbonate |
pH adjustment |
Variable |
FDA-approved formulations specify pH range between 4.3 and 5.0 to optimize stability |
| Water for injection |
Solvent |
As needed |
USP Grade |
| Sodium hydroxide |
pH adjustment |
As needed |
Used in small quantities, controlled tightly |
| Hydrochloric acid |
pH adjustment |
As needed |
Ensures formulation pH stability |
The excipients are selected based on stability data, compatibility with active ingredients, and patient tolerability.
How does excipient selection influence VABOMERE's stability and distribution?
Optimal excipient choice ensures:
- Chemical stability: pH buffers like sodium carbonate maintain meropenem stability, which is sensitive to pH fluctuations.
- Solubility: Water for injection allows quick reconstitution and infusion.
- Compatibility: Excipients do not react with active agents, preventing degradation.
- Safety: Excipients like sodium hydroxide and hydrochloric acid are in minimal, controlled amounts to avoid adverse reactions.
What are the commercial opportunities driven by excipient strategy?
Enhanced Formulation Stability
Investing in excipients that extend shelf life allows:
- Longer expiration dates (currently up to 24 months at controlled environments).
- Better logistics, reducing supply chain risks.
- Market expansion into regions with cold chain limitations.
Supplying High-Quality Excipients
Suppliers of pharmaceutical-grade excipients can:
- Secure contracts for VABOMERE manufacturing.
- License excipients with specific stability-enhancing properties.
- Develop novel excipients tailored for beta-lactam stability.
Differentiation through Improved Formulations
Research into alternative excipients like amber glass packaging, stabilizing polymers, or lyophilized formulations can:
- Improve stability profiles.
- Enable single-dose packaging.
- Appeal to markets requiring room temperature stability.
Regulatory and Competitive Edge
Proprietary excipient formulations, approved via supplemental NDA amendments, can:
- Provide patent protection.
- Enable differentiated product offerings.
- Reduce generic competition by maintaining formulation-specific barriers.
Market Expansion Opportunities
Region-specific formulations based on excipient stability can:
- Meet regulatory standards in emerging markets.
- Reduce cold chain dependency.
- Capture segments emphasizing robust stability.
Strategic Considerations for Excipient Development
- Compatibility testing with active ingredients.
- Scale-up manufacturing for large-volume excipient supply.
- Regulatory compliance across multiple jurisdictions.
- Intellectual property strategies for proprietary excipient formulations.
Regulatory Frameworks Affecting Excipient Use
- FDA Guidance (21 CFR Part 210 and 211) emphasizes excipient safety, especially for injectable drugs.
- EMA guidelines require detailed excipient profiling in dossiers.
- Differing regional policies influence excipient sourcing and formulation adjustments.
Key Takeaways
- VABOMERE’s excipients focus on pH stability, solubility, and compatibility.
- Formulation stability affects shelf life, logistics, and regional distribution.
- Opportunities exist in developing enhanced excipients and proprietary formulations.
- Regulatory pathways enable intellectual property protections for excipient innovations.
- Market growth hinges on stability, formulation improvements, and supply chain robustness.
FAQs
1. Can alternative excipients improve VABOMERE’s stability? Yes. Research into stabilizing polymers or buffered systems could extend shelf life and improve distribution.
2. Are excipient shortages a risk for VABOMERE? Potentially, especially during global supply constraints. Diversifying suppliers and developing local sources mitigate risk.
3. How does excipient choice impact patient safety? Excipients used are generally recognized as safe (GRAS) and comply with pharmacopeial standards. Careful control minimizes adverse reactions.
4. Is there scope for patenting new excipient formulations? Yes. Proprietary excipient combinations or stabilization techniques can be patented, providing competitive advantage.
5. What regulatory hurdles exist for excipient modifications? Changes necessitate supplemental filings, stability testing, and safety assessments to meet FDA and EMA standards.
References
- Food and Drug Administration (FDA). (2015). Guidance for Industry: Nonclinical Safety Evaluation of Drug/Excipients. U.S. Department of Health and Human Services.
- European Medicines Agency (EMA). (2018). Guideline on the Specification Limits for Product-Related Impurities. EMA.
- U.S. Pharmacopeia (USP). (2022). <791> pH.
- Conly, J. M., & Kaye, K. S. (2020). Antibiotic resistance and excipient impacts. Clinical Infectious Diseases, 70(9), 1981-1987.
- Kotha, S., & Saini, S. (2021). Advances in pharmaceutical excipient development. International Journal of Pharmaceutical Investigation, 11(2), 161–168.
